Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 85
Filter
2.
Am J Surg Pathol ; 46(1): 89-96, 2022 01 01.
Article in English | MEDLINE | ID: mdl-34081038

ABSTRACT

Approximately 20% of patients with symptomatic syndrome-associated coronavirus-2 (SARS-CoV-2) infection have gastrointestinal bleeding and/or diarrhea. Most are managed without endoscopic evaluation because the risk of practitioner infection outweighs the value of biopsy analysis unless symptoms are life-threatening. As a result, much of what is known about the gastrointestinal manifestations of coronavirus disease-2019 (COVID-19) has been gleaned from surgical and autopsy cases that suffer from extensive ischemic injury and/or poor preservation. There are no detailed reports describing any other gastrointestinal effects of SARS-CoV-2 even though >3,000,000 people have died from COVID-19 worldwide. The purpose of this study is to report the intestinal findings related to SARS-CoV-2 infection by way of a small case series including one with evidence of direct viral cytopathic effect and 2 with secondary injury attributed to viral infection. Infection can be confirmed by immunohistochemical stains directed against SARS-CoV-2 spike protein, in situ hybridization for spike protein-encoding RNA, and ultrastructural visualization of viruses within the epithelium. It induces cytoplasmic blebs and tufted epithelial cells without inflammation and may not cause symptoms. In contrast, SARS-CoV-2 infection can cause gastrointestinal symptoms after the virus is no longer detected, reflecting systemic activation of cytokine and complement cascades rather than direct viral injury. Reversible mucosal ischemia features microvascular injury with hemorrhage, small vessel thrombosis, and platelet-rich thrombi. Systemic cytokine elaboration and dysbiosis likely explain epithelial cell injury that accompanies diarrheal symptoms. These observations are consistent with clinical and in vitro data and contribute to our understanding of the protean manifestations of COVID-19.


Subject(s)
COVID-19/pathology , Intestinal Diseases/pathology , Intestinal Diseases/virology , Intestines/pathology , Intestines/virology , Adult , Aged , Aged, 80 and over , Biomarkers/metabolism , Biopsy , COVID-19/diagnosis , COVID-19/immunology , Cytokines/metabolism , Gastrointestinal Hemorrhage/diagnosis , Gastrointestinal Hemorrhage/immunology , Gastrointestinal Hemorrhage/pathology , Gastrointestinal Hemorrhage/virology , Humans , Intestinal Diseases/diagnosis , Intestinal Diseases/immunology , Intestines/immunology , Ischemia/diagnosis , Ischemia/immunology , Ischemia/pathology , Ischemia/virology , Male , Thrombosis/diagnosis , Thrombosis/immunology , Thrombosis/pathology , Thrombosis/virology
3.
Arab J Gastroenterol ; 22(2): 177-179, 2021 Jun.
Article in English | MEDLINE | ID: mdl-34090835

ABSTRACT

Despite the emerging data about the thrombophilic effect of the novel coronavirus [1] , the relation between coagulation disorders and the COVID-19 pandemic is still not well understood. Various studies pointed to the significant role of the COVID-19 induced cytokine storm in development of the hypercoagulable state which leads to serious thromboembolic complications [2,3] . Some studies report the development of severe immune thrombocytopenia induced by the novel coronavirus [4] . Other studies found a correlation between COVID-19 disease and the development of disseminated intravascular coagulation (DIC) [5]. Patients with severe COVID-19 disease have an increased risk for development of gastrointestinal bleeding (GI) which may be related to stress [6] , critical illness or mechanical ventilation [7] . Further studies showed the ability of the novel coronavirus to infect the epithelial cells of the GI tract [8] . Moreover, some data pointed to the ability of the virus even to infect the endothelium of blood vessels [9]. The relation between the COVID-19 pandemic and GI bleeding deserves more studies [10]. We present a case of GI bleeding in a patient with severe COVID-19 disease. We assume that COVID-19 disease can be a predominant factor for the development of DIC and GI bleeding.


Subject(s)
COVID-19 , Gastrointestinal Hemorrhage/virology , Blood Coagulation Disorders , COVID-19/complications , Humans , Pandemics
6.
Article in English | MEDLINE | ID: mdl-33436481

ABSTRACT

We present a case of haemorrhagic enterocolitis in a patient with SARS-CoV-2 who recovered from respiratory failure after support with venovenous extracorporeal membrane oxygenation. We describe clinicopathological features consistent with the systemic coinfection/reactivation of cytomegalovirus (CMV) concurrent with COVID-19 infection and the protracted clinical course of resolution of gastrointestinal inflammation after the treatment of CMV infection. Stool PCR, abdominal CT perfusion scan and histological examination of ileal and colonic tissues excluded enterocolitis secondary to other causes of infection (common viral, bacterial and protozoal gastrointestinal pathogens), macrovascularand microvascular ischaemia and classic inflammatory bowel disease, respectively. We propose possible synergistic pathophysiologic mechanisms for enterocolitis complicating severe COVID-19 infection: (1) T lymphocyte depletion and immune response dysregulation, (2) use of immunomodulators in the management of severe COVID-19 infection and (3) high concentration of ACE-2 receptors for COVID-19 virus in the gastrointestinal tract.


Subject(s)
COVID-19/complications , Coinfection/virology , Cytomegalovirus Infections/complications , Enterocolitis/complications , Gastrointestinal Hemorrhage/virology , COVID-19/therapy , Diarrhea/virology , Enterocolitis/virology , Extracorporeal Membrane Oxygenation , Female , Humans , Middle Aged , SARS-CoV-2
7.
Turk J Gastroenterol ; 31(9): 620-625, 2020 09.
Article in English | MEDLINE | ID: mdl-33090098

ABSTRACT

BACKGROUND/AIMS: This study aimed to provide supporting evidence for prevention and prognostic evaluation of bleeding complications in the early stage by exploring the risk and predicting factors in patients with acute-on-chronic liver failure (ACLF). MATERIALS AND METHODS: A total of 101 hospitalized patients with ACLF were retrospectively included from January 1, 2014 to December 31, 2015. The patients were divided into bleeding (n=38) and nonbleeding groups (n=63). Demographic data and laboratory tests were recorded and compared between the two groups. The incidence, risk factors, and prognosis of bleeding complications among patients with ACLF were investigated. RESULTS: A total of 38 cases (37.62%) had bleeding complications: 26 (25.74%) were spontaneous and 12 (11.88%) were postprocedural. Patients with bleeding complications had lower platelet (p=0.008), fibrinogen (p<0.001), factor V (p=0.001), and factor VII (p=0.026) levels; higher serum creatinine levels (p=0.004); and a higher proportion of cirrhosis (p=0.013). Logistic regression analysis showed that cirrhosis (odds ratio=3.251, p=0.046), fibrinogen level (odds ratio=0.352, p=0.007), and factor VII level (odds ratio=0.951, p=0.011) contributed to the development of bleeding complications. A subgroup analysis of invasive manipulation-induced bleeding complications showed lower levels of factors V (p=0.018) and VII (p=0.021) in the postprocedural bleeding group. Follow-up studies showed that the nonbleeding group had a higher survival rate than the bleeding group at day 90 (73.33% versus 51.85%, p=0.040). CONCLUSION: Liver cirrhosis, lower levels of fibrinogen, and major coagulation factor activity in patients with ACLF were associated with an elevated risk of bleeding events during hospitalization, which further impaired the 90-day survival rate.


Subject(s)
Acute-On-Chronic Liver Failure/blood , Gastrointestinal Hemorrhage/etiology , Gastrointestinal Hemorrhage/mortality , Hepatitis B virus , Hepatitis B/blood , Acute-On-Chronic Liver Failure/complications , Acute-On-Chronic Liver Failure/virology , Adult , Aged , Blood Coagulation Factors/analysis , Factor VII/analysis , Female , Fibrinogen/analysis , Gastrointestinal Hemorrhage/virology , Hepatitis B/complications , Hepatitis B/virology , Hospitalization/statistics & numerical data , Humans , Incidence , Logistic Models , Male , Middle Aged , Odds Ratio , Predictive Value of Tests , Prognosis , Retrospective Studies , Risk Factors , Survival Rate
8.
BMC Gastroenterol ; 20(1): 318, 2020 Sep 29.
Article in English | MEDLINE | ID: mdl-32993509

ABSTRACT

BACKGROUND: SARS-CoV-2 is highly infectious and has been a significant public health threat. Despite typical manifestations of illness are dominated by respiratory symptom, some patients have concurrent gastrointestinal manifestations, including nausea, diarrhea, and vomiting. Massive gastrointestinal bleeding, however, has rarely been reported. CASE PRESENTATION: We herein described a case of severe SARS-CoV-2 infected patient with several risk factors for poor prognosis, including male, hypertension, old age, mixed bacterial infection and multilobular infiltration on radiological imaging. After improvement of respiratory status, the onset of gastrointestinal bleeding occurred, probably resulting from direct viral invasion as evidenced by the positive findings for SARS-CoV-2 in the repeat stool specimens. Although aggressive resuscitation was administered, hematochezia was uncontrolled. The patient rapidly deteriorated, suffered from cardiac arrest, and expired. CONCLUSIONS: Digestive symptoms could be severe in SARS-CoV-2 infected patients, especially for the high-risk individuals with predisposing conditions. A more thorough protocol for preventing cross-infection through faecal-oral transmission should be implemented in the process of patient care and infection control.


Subject(s)
Betacoronavirus , Coronavirus Infections/complications , Coronavirus Infections/mortality , Gastrointestinal Hemorrhage/virology , Pneumonia, Viral/complications , Pneumonia, Viral/mortality , Aged, 80 and over , COVID-19 , Coronavirus Infections/therapy , Fatal Outcome , Gastrointestinal Hemorrhage/diagnosis , Gastrointestinal Hemorrhage/therapy , Humans , Male , Pandemics , Pneumonia, Viral/therapy , Risk Factors , SARS-CoV-2
10.
J Cancer Res Ther ; 16(1): 167-169, 2020.
Article in English | MEDLINE | ID: mdl-32362630

ABSTRACT

Lymphoproliferative malignancies can involve both nodal- and extra-nodal tissues. The most common extranodal site involved is the gastrointestinal (GI) tract, and it is secondary to the widespread primary nodal disease. However, about 33% of non-Hodgkin's lymphoma primarily arise from tissues other than lymph nodes, spleen, or bone marrow, for example, GI tract, skin, or the central nervous system and are called primary extranodal lymphomas. The most common site of GI localization is stomach (50%-60%) followed by small bowel. Primary colonic lymphoma is seen only in 6% of GI lymphomas and up to 0.5%-1% of all colon malignancies. Hence, primary GI lymphoma is extremely rare, and primary colonic lymphoma is an even rarer occurrence. There is clearly a paucity of cases reported in literature resulting in unclear treatment protocol. Here, we report a case of a 51-year-old man who presented with abdominal pain, weight loss, and bright red blood per rectum. A colonoscopy revealed diffuse bleeding ulcers involving the entire colon. Pathology was consistent with primary diffuse large B-cell lymphoma arising from the colon. The patient was started on treatment with rituximab, cyclophosphamide, adriamycin, vincristine, and prednisone.


Subject(s)
Colonic Neoplasms/virology , Epstein-Barr Virus Infections/complications , Gastrointestinal Hemorrhage/virology , Herpesvirus 4, Human/isolation & purification , Lymphoma, Large B-Cell, Diffuse/virology , Adult , Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Colonic Neoplasms/drug therapy , Colonic Neoplasms/pathology , Epstein-Barr Virus Infections/virology , Gastrointestinal Hemorrhage/drug therapy , Gastrointestinal Hemorrhage/pathology , Humans , Lymphoma, Large B-Cell, Diffuse/drug therapy , Lymphoma, Large B-Cell, Diffuse/pathology , Male , Prognosis
11.
BMC Infect Dis ; 20(1): 281, 2020 Apr 15.
Article in English | MEDLINE | ID: mdl-32295538

ABSTRACT

BACKGROUND: Severe fever with thrombocytopenia syndrome (SFTS) is an emerging infectious disease that commonly has a lethal course caused by the tick-borne Huaiyangshan banyang virus [former SFTS virus (SFTSV)]. The viral load in various body fluids in SFTS patients and the best infection control measure for SFTS patients have not been fully established. CASE PRESENTATION: A 79-year-old man was bitten by a tick while working in the bamboo grove in Nagasaki Prefecture in the southwest part of Japan. Due to the occurrence of impaired consciousness, he was referred to Nagasaki University Hospital for treatment. The serum sample tested positive for SFTSV-RNA in the genome amplification assay, and he was diagnosed with SFTS. Furthermore, SFTSV-RNA was detected from the tick that had bitten the patient. He was treated with multimodal therapy, including platelet transfusion, antimicrobials, antifungals, steroids, and continuous hemodiafiltration. His respiration was assisted with mechanical ventilation. On day 5, taking the day on which he was hospitalized as day 0, serum SFTSV-RNA levels reached a peak and then decreased. However, the cerebrospinal fluid collected on day 13 was positive for SFTSV-RNA. In addition, although serum SFTSV-RNA levels decreased below the detectable level on day 16, he was diagnosed with pneumonia with computed tomography. SFTSV-RNA was detected in the bronchoalveolar lavage fluid on day 21. By day 31, he recovered consciousness completely. The pneumonia improved by day 51, but SFTSV-RNA in the sputum remained positive for approximately 4 months after disease onset. Strict countermeasures against droplet/contact infection were continuously conducted. CONCLUSIONS: Even when SFTSV genome levels become undetectable in the serum of SFTS patients in the convalescent phase, the virus genome remains in body fluids and tissues. It may be possible that body fluids such as respiratory excretions become a source of infection to others; thus, careful infection control management is needed.


Subject(s)
Body Fluids/virology , Brain Diseases/virology , Bunyaviridae Infections/epidemiology , Gastrointestinal Hemorrhage/virology , Phlebovirus/genetics , Pneumonia/virology , RNA, Viral/blood , Aged , Animals , Brain Diseases/drug therapy , Bronchoalveolar Lavage Fluid/virology , Bunyaviridae Infections/drug therapy , Bunyaviridae Infections/virology , Combined Modality Therapy , Gastrointestinal Hemorrhage/drug therapy , Hospitals, University , Humans , Japan/epidemiology , Male , Nucleic Acid Amplification Techniques , Phlebovirus/isolation & purification , Pneumonia/drug therapy , Sputum/virology , Ticks/virology , Treatment Outcome , Viral Load
13.
Sci Rep ; 9(1): 16367, 2019 11 08.
Article in English | MEDLINE | ID: mdl-31705016

ABSTRACT

Feline bocavirus-1 (FBoV-1) was identified in cats from different households with hemorrhagic enteritis during outbreaks of an unusual clinical presentation of feline panleukopenia virus (FPLV) in Thailand. Use of polymerase chain reaction revealed the presence of the FBoV-1 DNA in several tissues, suggesting hematogenous viremia, with the viral nucleic acid, detected by in situ hybridization (ISH), was localized in intestinal cells and vascular endothelium of intestinal mucosa and serosa, and in necrosis areas primarily in various lymph nodes while FPLV-immunohistochemical analysis revealed viral localization only in cryptal cells, neurons, and limited to leukocytes in the mesenteric lymph node. Full-length coding genome analysis of the Thai FBoV-1 strains isolated from moribund cats revealed three distinct strains with a high between-strain genetic diversity, while genetic recombination in one of the three FBoV-1 strains within the NS1 gene. This is the first report identifying natural genetic recombination of the FBoV-1 and describing the pathology and viral tropism of FBoV-1 infection in cats. Although the role of FBoV-1 associated with systemic infection of these cats remained undetermined, a contributory role of enteric infection of FBoV-1 is possible. Synergistic effects of dual infection with FPLV and FBoV-1 are hypothesized, suggesting more likely severe clinical presentations.


Subject(s)
Bocavirus/isolation & purification , Cat Diseases/pathology , Enteritis/veterinary , Gastrointestinal Hemorrhage/veterinary , Parvoviridae Infections/veterinary , Recombination, Genetic , Viral Tropism , Animals , Bocavirus/classification , Bocavirus/genetics , Cat Diseases/epidemiology , Cat Diseases/virology , Cats , DNA, Viral/analysis , Disease Outbreaks , Enteritis/epidemiology , Enteritis/virology , Gastrointestinal Hemorrhage/epidemiology , Gastrointestinal Hemorrhage/virology , Parvoviridae Infections/epidemiology , Parvoviridae Infections/virology , Phylogeny , Thailand/epidemiology
14.
J Vet Diagn Invest ; 31(5): 732-736, 2019 Sep.
Article in English | MEDLINE | ID: mdl-31291838

ABSTRACT

A 5-mo-old Bassett Hound-Labrador Retriever cross was autopsied following a bout of lethargy, inappetence, and bleeding gums. Mucous membranes were white, and the small intestine was blue-black; the colon contained black feces. The spleen was swollen, and multiple lymph nodes were enlarged and hemorrhagic. Microscopically, the small intestine had focal crypt cell necrosis and circumferential transmural vasculitis, the latter the cause of infarction and the blue-black coloration. Lymphocytes were necrotic in spleen and lymph nodes, and erythrophagocytosis was present in some nodes. Vasculitis was present in brain, meninges, lung, liver, and kidneys. Electron microscopy revealed aggregates of 15-18 nm round viral particles in damaged crypt cells and in the endothelium of small blood vessels. Electron-dense intracytoplasmic inclusions consisting of paracrystalline-arrayed virus were demonstrated in macrophages in medullary lymph node sinuses. These virions were identified as circovirus, which was confirmed by real-time PCR and sequencing.


Subject(s)
Circoviridae Infections/veterinary , Circovirus/isolation & purification , Dog Diseases/virology , Enteritis/veterinary , Gastrointestinal Hemorrhage/veterinary , Animals , Autopsy/veterinary , Circoviridae Infections/pathology , Circoviridae Infections/virology , Connecticut , Dog Diseases/pathology , Dogs , Enteritis/pathology , Enteritis/virology , Fatal Outcome , Gastrointestinal Hemorrhage/pathology , Gastrointestinal Hemorrhage/virology , Intestine, Small/pathology , Kidney/pathology , Liver/pathology , Lymph Nodes/pathology , Microscopy, Electron/veterinary , Necrosis/pathology , Necrosis/veterinary , Real-Time Polymerase Chain Reaction , Spleen/pathology
15.
BMC Gastroenterol ; 19(1): 101, 2019 Jun 21.
Article in English | MEDLINE | ID: mdl-31226942

ABSTRACT

BACKGROUND: The preventive effects of antiviral therapy to reduce rebleeding rate in patients with hepatitis B-related cirrhosis undergoing endoscopic treatment have not yet been reported. METHODS: In this retrospective cohort study, 1139 patients with chronic hepatitis B with first acute variceal bleeding after endoscopic therapy from September 2008 to December 2017 were included. Among them, 923 who received and 216 who did not receive antiviral therapy were followed up for rebleeding. Cumulative rebleeding rate was calculated using the Kaplan-Meier method. Univariate and multivariate logistic regression analyses were performed to estimate the effects of antiviral therapy on rebleeding risk. The propensity score matched method and inverse probability of treatment weighting analysis were used to calculate the rebleeding rate between the antiviral and non-antiviral groups. RESULTS: The rebleeding rates were 40.5, 60.7, 72.6, and 89.2% in antiviral group at 1, 2, 3, and 5 years, respectively. The corresponding rebleeding rates in the non-antiviral group were 54.2, 72.4, 84.4, and 93.3%, respectively. The multivariate logistic regression analysis revealed that antiviral therapy was an independent protective factor associated with rebleeding. CONCLUSION: Antiviral treatment significantly reduced rebleeding rate in patients with HBV-related cirrhosis who received endoscopic treatment after the first variceal bleeding.


Subject(s)
Antiviral Agents/therapeutic use , Endoscopy/adverse effects , Esophageal and Gastric Varices/prevention & control , Gastrointestinal Hemorrhage/prevention & control , Hepatitis B virus , Hepatitis B, Chronic/complications , Liver Cirrhosis/surgery , Postoperative Complications/prevention & control , Acute Disease , Esophageal and Gastric Varices/epidemiology , Esophageal and Gastric Varices/virology , Female , Gastrointestinal Hemorrhage/epidemiology , Gastrointestinal Hemorrhage/virology , Hepatitis B, Chronic/virology , Humans , Kaplan-Meier Estimate , Liver Cirrhosis/virology , Logistic Models , Male , Middle Aged , Postoperative Complications/epidemiology , Postoperative Complications/virology , Propensity Score , Protective Factors , Recurrence , Retrospective Studies , Risk Factors , Treatment Outcome
17.
Eur J Gastroenterol Hepatol ; 31(2): 241-247, 2019 02.
Article in English | MEDLINE | ID: mdl-30281535

ABSTRACT

BACKGROUND: Noninvasive methods have been established to detect clinically significant portal hypertension in liver cirrhosis with variable limitations. The von Willebrand factor (vEF) has been found to increase in liver cirrhosis. AIM: The aim of this study was to explore the vEF and VITRO (von Willebrand factor antigen/platelet ratio) score in the prediction of variceal bleeding in patients with portal hypertension. MATERIALS AND METHODS: Fifty patients with hepatitis C-related liver cirrhosis (25 patients with variceal bleeding and 25 without variceal bleeding) as well as 80 healthy controls were included. Laboratory investigations and upper gastrointestinal endoscopy were performed in all patients. Serum vEF was measured in the patient and the control group. The VITRO score was calculated. RESULTS: The mean levels of the vEF antigen and the VITRO score were higher in patients with variceal bleeding compared with patients without variceal bleeding and controls (P<0.001). At levels of at least 100.1 ng/ml and at least 0.732, the vEF and the VITRO score could predict variceal bleeding with a sensitivity and a specificity of 92 and 99.9% for the vEF and 80 and 68% for the VITRO score (area under the curve=0.982 and 0.843), respectively. Levels of vEF were correlated positively with esophageal varices grade. CONCLUSION: Serum vEF level and the VITRO score are potential noninvasive biomarkers for the prediction and risk stratification of variceal bleeding in hepatitis C-related liver cirrhosis.


Subject(s)
Blood Platelets , Decision Support Techniques , Esophageal and Gastric Varices/blood , Gastrointestinal Hemorrhage/blood , Hepatitis C/complications , Hypertension, Portal/blood , Liver Cirrhosis/blood , von Willebrand Factor/analysis , Biomarkers/blood , Case-Control Studies , Cross-Sectional Studies , Esophageal and Gastric Varices/diagnosis , Esophageal and Gastric Varices/virology , Female , Gastrointestinal Hemorrhage/diagnosis , Gastrointestinal Hemorrhage/virology , Hepatitis C/diagnosis , Hepatitis C/virology , Humans , Hypertension, Portal/diagnosis , Hypertension, Portal/virology , Liver Cirrhosis/diagnosis , Liver Cirrhosis/virology , Male , Middle Aged , Platelet Count , Predictive Value of Tests , Prognosis , Prospective Studies , Risk Factors , Severity of Illness Index , Up-Regulation
18.
Viruses ; 10(10)2018 09 20.
Article in English | MEDLINE | ID: mdl-30241284

ABSTRACT

In the 2014⁻2016 West Africa Ebola Virus (EBOV) outbreak, there was a significant concern raised about the potential for secondary bacterial infection originating from the gastrointestinal tract, which led to the empiric treatment of many patients with antibiotics. This retrospective pathology case series summarizes the gastrointestinal pathology observed in control animals in the rhesus EBOV-Kikwit intramuscular 1000 plaque forming unit infection model. All 31 Non-human primates (NHPs) exhibited lymphoid depletion of gut-associated lymphoid tissue (GALT) but the severity and the specific location of the depletion varied. Mesenteric lymphoid depletion and necrosis were present in 87% (27/31) of NHPs. There was mucosal barrier disruption of the intestinal tract with mucosal necrosis and/or ulceration most notably in the duodenum (16%), cecum (16%), and colon (29%). In the intestinal tract, hemorrhage was noted most frequently in the duodenum (52%) and colon (45%). There were focal areas of bacterial submucosal invasion in the gastrointestinal (GI) tract in 9/31 (29%) of NHPs. Only 2/31 (6%) had evidence of pancreatic necrosis. One NHP (3%) experienced jejunal intussusception which may have been directly related to EBOV. Immunofluorescence assays demonstrated EBOV antigen in CD68+ macrophage/monocytes and endothelial cells in areas of GI vascular injury or necrosis.


Subject(s)
Ebolavirus/immunology , Gastrointestinal Tract/pathology , Hemorrhagic Fever, Ebola/pathology , Animals , Antigens, CD/immunology , Antigens, Differentiation, Myelomonocytic/immunology , Antigens, Viral/immunology , Cohort Studies , Disease Models, Animal , Female , Gastrointestinal Hemorrhage/pathology , Gastrointestinal Hemorrhage/virology , Gastrointestinal Tract/virology , Humans , Lymphoid Tissue/pathology , Lymphoid Tissue/virology , Macaca mulatta , Male , Necrosis/pathology , Necrosis/virology , Retrospective Studies
20.
Am J Case Rep ; 19: 912-916, 2018 Aug 03.
Article in English | MEDLINE | ID: mdl-30072684

ABSTRACT

BACKGROUND Hemorrhagic duodenitis is an exceptionally rare adverse event of sodium polystyrene sulfonate (SPS) treatment and is a common manifestation of cytomegalovirus (CMV) reactivation. SPS is known to cause marked inflammation in the lower gastrointestinal tract, including colonic necrosis, whereas involvement of the small bowel is uncommon. Although its effectiveness and safety has been disputed since its introduction, SPS remains widely used due to lack of alternatives. CMV infection and reactivation are well-known complications after solid-organ transplantation, particularly in seronegative recipients receiving organs from seropositive donors, and is associated with significant morbidity and mortality. The lower gastrointestinal tract is more commonly involved, but infections of all parts of the intestine are observed. CASE REPORT Here, we report the case of a 56-year-old man who presented with severe upper-gastrointestinal bleeding. Hemorrhagic duodenitis was initially attributed to the use of SPS, as abundant SPS crystals were detected in the duodenal mucosa but we found only 2 CMV-infected endothelial cells. Two weeks later, gastrointestinal bleeding recurred. However, this time, abundant CMV-infected cells were demonstrated in the duodenal biopsies. CONCLUSIONS Our case report highlights an uncommon adverse event after SPS use with a simultaneous CMV reactivation. The main difficulty was to differentiate between CMV reactivation and CMV as an "innocent bystander". This demonstrates the challenge of decision-making in patients with complex underlying diseases.


Subject(s)
Cation Exchange Resins/adverse effects , Cytomegalovirus Infections/etiology , Duodenitis/etiology , Gastrointestinal Hemorrhage/etiology , Polystyrenes/adverse effects , Cytomegalovirus/isolation & purification , Cytomegalovirus Infections/virology , Duodenitis/pathology , Gastrointestinal Hemorrhage/chemically induced , Gastrointestinal Hemorrhage/virology , Humans , Hyperkalemia/drug therapy , Kidney Transplantation/adverse effects , Male , Middle Aged
SELECTION OF CITATIONS
SEARCH DETAIL
...